Rekvina Labs Ltd, a Public Limited Company incorporated in England and Wales on 1st November 1988, specializes in the manufacturing and marketing of pharmaceutical products. However, the company currently operates primarily in the copper extrusion business segment. In 2015, Rekvina Labs restructured its equity by subdividing its shares, issuing two Rs. 5/- shares for each Rs. 10/- share held.
In 2017, the company issued 10,769,867 shares, primarily under the Mobeus VCTs' Linked Offer for Subscription, and through its Dividend Investment Scheme. Additionally, Rekvina Labs conducted a share buyback of 553,800 shares at an average price of 95.28 pence, with a total expenditure of 527,637 pounds, subsequently canceling these shares, which constituted 0.9% of its issued share capital as of October 2014. This strategic move potentially aimed to enhance shareholder value and streamline its capital structure.
